John Green and Tuberculosis

What It Covers

Author John Green and journalist Dan Weissman examine how Johnson & Johnson used secondary drug patents to restrict access to bedaquiline, a tuberculosis drug, affecting an estimated 1.4 million patients annually. India's Section 3D patent law, two TB survivors' legal victory, and Green's nerdfighter community combined to pressure J&J into expanding generic access.

Key Questions Answered

• •Patent Evergreening Mechanics: Drug companies routinely file dozens of secondary patents on existing drugs to extend monopoly protection far beyond the standard 20-year term. A study of the 12 best-selling US drugs found an average of 131 patents each, translating to an average of 38 years of effective patent protection rather than 20.
• •India's Section 3D as a Legal Tool: India's patent law requires companies seeking secondary patents on existing drug formulations to prove increased therapeutic efficacy — not just a reformulation. This provision successfully blocked J&J's secondary bedaquiline patent in March 2023, immediately enabling Indian generic manufacturers to produce affordable versions of the drug.
• •Strategic Patent Filing Timing: Pharmaceutical companies deliberately delay filing secondary patents to maximize back-end protection. One patent attorney's documented advice instructs companies to wait two to three years during drug discovery before filing add-on patents. J&J waited four years before filing bedaquiline's salt formulation patent, extending their monopoly accordingly.
• •Coordinated Advocacy Sequencing: Effective pharmaceutical advocacy requires layering legal challenges, survivor testimony, and mass public pressure in sequence. Tahir Amin's IMAK spent nearly 20 years building India's legal framework; TB survivors Fumesa Tesile and Nandita Venkateshian filed the patent challenge; only then did John Green's audience amplify pressure — producing J&J's policy concession within one week.
• •US Patent Policy Has Global Consequences: IMAK shifted 80% of its work to the United States because US patent office practices and World Trade Organization policies shaped by US pharmaceutical companies set global standards. Reforming how the US Patent Office evaluates and grants secondary drug patents would directly affect drug access in low- and middle-income countries worldwide.